BDX · 10-Q · 2026Q2 · Full report

Trade Policy and Tariffs

BECTON DICKINSON & CO · 2026-08-06 · Importance 40 · Surprise 42 · In source text

Tariffs, sanctions and other trade barriers imposed by or against the United States adversely affected BD’s third-quarter fiscal 2026 operating expense and are expected to continue affecting fiscal 2026 and potentially later periods. The exposure primarily relates to products and components imported from countries across BD’s global supply chain that do not qualify for exemptions, with impacts also reflected in gross margins for the Medical Essentials, BioPharma Systems and Interventional segments. BD is pursuing sourcing optimization, tariff exemptions and refunds of certain tariffs, but the collectability of the remaining exemption-claim receivable remains uncertain because mitigation strategies could be challenged, rejected or eliminated.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
operating_incomenegativeprobableTariffs adversely impacted BD's third quarter fiscal year 2026 operating expense and BD expects a continued adverse impact to operating…